Table 4.
Severity of adverse events (AEs) detected in patients receiving home healthcare classified by origin
| Severity category | Home healthcare | Care outside home healthcare | Total | |||
| AE, n (%; 95% CI) |
Preventable AE, n (%; 95% CI) |
AE, n (%; 95% CI) |
Preventable AE, n (%; 95% CI) |
AE, n (%; 95% CI) |
Preventable AE, n (%; 95% CI) |
|
| Severity category according to NCCP MERP index | ||||||
| E, Contributed to or resulted in temporary harm | 78 (28.8; 22.9 to 35.7) | 50 (64.1; 48.1 to 83.8) | 24 (28.2; 18.5 to 41.4) | 14 (58.3; 33.2 to 95.6) | 102 (28.6; 23.5 to 34.6) | 64 (62.7; 48.7 to 79.6) |
| F, Contributed to or resulted in temporary harm to the patient and required outpatient, home health or hospital care or prolonged hospitalisation or an extended period of home healthcare | 187 (69.0; 59.6 to 79.4) | 142 (75.9; 64.2 to 89.2) | 59 (69.4; 53.3 to 88.9) | 45 (76.3; 56.3 to 101.2) | 246 (69.1; 60.9 to 78.2) | 187 (76.0; 65.7 to 87.5) |
| G, Contributed to or resulted in permanent patient harm | 3 (1.1; 0.3 to 3.0) | 1 (33.3; 1.7 to 164.4) | 2 (2.4; 3.9 to 7.8) | 2 (100; 167.7 to 330.4) | 5 (1.4; 0.5 to 3.1) | 3 (60.0; 15.3 to 163.3) |
| H, Life-saving intervention required within 60 min | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| I, Contributed to patient ‘s death | 3 (1.1; 0.3 to 3.0) | 1 (33.3; 1.7 to 164.4) | 0 (0) | 0 (0) | 3 (0.8; 0.2 to 2.3) | 1 (33.3; 1.7 to 164.4) |
| Total | 271 (100) | 194 (71.6; 62.0 to 82.2) | 85 (100) | 61 (71.8; 55.4 to 91.6) | 356 (100) | 255 (71.6; 63.2 to 80.8) |
| Severity category according to HMPS scale | ||||||
| Minimal impairment, recovery within 1 month | 171 (63.1; 54.2 to 73.1) | 118 (69.0; 57.4 to 82.3) | 42 (49.4; 36.1 to 66.2) | 31 (73.8; 51.0 to 103.5) | 213 (59.8; 52.2 to 68.3) | 149 (69.9; 59.4 to 81.9) |
| Moderate impairment, recovery within 1–6 months | 57 (21.0; 16.1 to 27.0) | 44 (77.2; 56.8 to 102.7) | 26 (30.6; 20.4 to 44.2) | 19 (73.1; 45.3 to 112.0) | 83 (23.3; 18.7 to 28.8) | 63 (75.9; 58.8 to 96.5) |
| Moderate impairment, recovery within 6–12 months | 14 (5.2; 2.9 to 8.5) | 11 (78.6; 41.3 to 136.6) | 1 (1.2; 0.1 to 5.8) | 0 (0) | 15 (4.2; 2.5 to 6.8) | 11 (73.3; 38.6 to 127.5) |
| Permanent impairment, degree of disability ≤50% | 3 (1.1; 0.3 to 3.0) | 1 (33.3; 1.7 to 164.4) | 2 (2.4; 0.4 to 7.8) | 2 (100; 167.7 to 330.4) | 5 (1.4; 0.5 to 3.1) | 3 (60.0; 15.3 to 163.3) |
| Permanent impairment, degree of disability >50% | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Contributed to patient death | 3 (1.1; 0.3 to 3.0) | 1 (33.3; 1.7 to 164.4) | 0 (0) | 0 (0) | 3 (0.8; 0.2 to 2.3) | 1 (33.3; 1.7 to 164.4) |
| Unable to determine | 23 (8.5; 5.5 to 12.5) | 19 (82.6; 51.2 to 126.6) | 14 (16.5; 9.4 to 27.0) | 9 (64.3; 31.4 to 118.0) | 37 (10.4; 7.4 to 14.2) | 28 (75.7; 51.3 to 107.9) |
| Total | 271 (100) | 194 (71.6; 62.0 to 82.2) | 85 (100) | 61 (71.8; 55.4 to 91.6) | 356 (100) | 255 (71.6; 63.2 to 80.8) |
HMPS, Harvard Medical Practice Study; NCCP MERP, National Coordinating Council for Medication Error Reporting and Prevention.